Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747511 | 0.91 | DHFR (0.64) | DHFRNPC1RAB9A | |
| SCHEMBL6744375 | 0.87 | DHFR (0.55) | DHFR | |
| SCHEMBL6748545 | 0.85 | DHFR (0.58) | DHFRKDM4ELMNA | |
| SCHEMBL6748619 | 0.82 | DHFR (0.52) | DHFR | |
| SCHEMBL6747477 | 0.81 | DHFR (0.51) | DHFR | |
| SCHEMBL6751096 | 0.81 | DHFR (0.57) | DHFR | |
| SCHEMBL6747595 | 0.80 | DHFR (0.52) | DHFR | |
| SCHEMBL6827626 | 0.80 | TDP1 (0.56) | DHFRRAB9AKDM4ETDP1 | |
| SCHEMBL6745912 | 0.79 | DHFR (0.59) | DHFR | |
| SCHEMBL6744621 | 0.79 | DHFR (0.56) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092515-A1 | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | MELACURE THERAPEUTICS AB (SE) | 2004-05-13 | — | — | US | disclosed |
| EP-1366028-A1 | DIAMINOQUINAZOLINE ESTERS FOR USE AS DIHYDROFOLATE REDUCTASE INHIBITORS | Melacure Therapeutics AB (SE) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068397-A1 | DIAMINOQUINAZOLINE ESTERS FOR USE AS DIHYDROFOLATE REDUCTADE INHIBITORS | MELACURE THERAPEUTICS AB (SE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092515-A1 | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | DHFR, DPYD, DHODH | DHFR 1/4885NPC1 2126/4885RAB9A 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.